MOSAIC: A model to assess the cost-effectiveness of remdesivir for admitted COVID-19 patients in South Africa

MODEL STRATEGIESThis model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or deathFour competing strategies are modelled:1. The "status quo" summarizes costs and outcomes for patients assuming no dexamethasone or remdesivir2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming dexamethasone at 6mg/day3. The "remdesivir" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day4. The "remdesivr plus dexamethasone" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day plus dexamethasone at 6mg/dayMODEL OUTCOMESCost: mean cost (general ward, ICU, dexamethasone and remdesivir as appropriate) per admitted patient from the health care provider's perspectiveHealth outcomes: mean DALYs and deaths per admitted patient Other outcomes: mean ICU days and inpatient days per admitted patientBudget impact: mean costs (or savings) associated with intervention implementation